Literature DB >> 27264121

Parkinson's disease and the Stroop color word test: processing speed and interference algorithms.

Shannon M Sisco1, Elizabeth Slonena2, Michael S Okun3, Dawn Bowers2,3, Catherine C Price2.   

Abstract

OBJECTIVE: Processing speed alters the traditional Stroop calculations of interference. Consequently, alternative algorithms for calculating Stroop interference have been introduced to control for processing speed, and have done so in a multiple sclerosis sample. This study examined how these processing speed correction algorithms change interference scores for individuals with idiopathic Parkinson's disease (PD, n = 58) and non-PD peers (n = 68).
METHOD: Linear regressions controlling for demographics predicted group (PD vs. non-PD) differences for Jensen's, Golden's, relative, ratio, and residualized interference scores. To examine convergent and divergent validity, interference scores were correlated with standardized measures of processing speed and executive function.
RESULTS: PD-non-PD differences were found for Jensen's interference score, but not Golden's score, or the relative, ratio, and residualized interference scores. Jensen's score correlated significantly with standardized processing speed but not executive function measures. Relative, ratio, and residualized scores correlated with executive function but not processing speed measures. Golden's score did not correlate with any other standardized measures.
CONCLUSIONS: The relative, ratio, and residualized scores were comparable for measuring Stroop interference in processing speed-impaired populations. Overall, the ratio interference score may be the most useful calculation method to control for processing speed in this population.

Entities:  

Keywords:  Parkinson’s; Stroop; interference; processing speed; psychometrics

Mesh:

Year:  2016        PMID: 27264121      PMCID: PMC5036998          DOI: 10.1080/13854046.2016.1188989

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  52 in total

1.  Trail making test, part B as a measure of executive control: validation using a set-switching paradigm.

Authors:  K Arbuthnott; J Frank
Journal:  J Clin Exp Neuropsychol       Date:  2000-08       Impact factor: 2.475

2.  The Trail Making Test.

Authors:  Jordi Llinàs-Reglà; Joan Vilalta-Franch; Secundino López-Pousa; Laia Calvó-Perxas; David Torrents Rodas; Josep Garre-Olmo
Journal:  Assessment       Date:  2016-07-28

3.  A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem.

Authors:  D A GRANT; E A BERG
Journal:  J Exp Psychol       Date:  1948-08

4.  SLAM: a connectionist model for attention in visual selection tasks.

Authors:  R H Phaf; A H Van der Heijden; P T Hudson
Journal:  Cogn Psychol       Date:  1990-07       Impact factor: 3.468

5.  The Stroop task: comparison between the original paradigm and computerized versions in children and adults.

Authors:  Iris-Katharina Penner; Maja Kobel; Markus Stöcklin; Peter Weber; Klaus Opwis; Pasquale Calabrese
Journal:  Clin Neuropsychol       Date:  2012-08-28       Impact factor: 3.535

6.  Stroop interference and negative priming in patients with multiple sclerosis.

Authors:  Melanie Vitkovitch; Sarah Bishop; Christine Dancey; Anne Richards
Journal:  Neuropsychologia       Date:  2002       Impact factor: 3.139

7.  Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging.

Authors:  M Baldereschi; A Di Carlo; W A Rocca; P Vanni; S Maggi; E Perissinotto; F Grigoletto; L Amaducci; D Inzitari
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

8.  Slowed central processing in simple and go/no-go reaction time tasks in Parkinson's disease.

Authors:  J A Cooper; H J Sagar; P Tidswell; N Jordan
Journal:  Brain       Date:  1994-06       Impact factor: 13.501

9.  Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction.

Authors:  Pekka Jokinen; Mira Karrasch; Anna Brück; Jarkko Johansson; Jörgen Bergman; Juha O Rinne
Journal:  J Neurol Sci       Date:  2013-04-03       Impact factor: 3.181

10.  Neuropsychological characteristics of preclinical dementia in Parkinson's disease.

Authors:  D M Jacobs; K Marder; L J Côté; M Sano; Y Stern; R Mayeux
Journal:  Neurology       Date:  1995-09       Impact factor: 9.910

View more
  5 in total

1.  Neuroimaging and biomarker evidence of neurodegeneration in asthma.

Authors:  Melissa A Rosenkranz; Douglas C Dean; Barbara B Bendlin; Nizar N Jarjour; Stephane Esnault; Henrik Zetterberg; Amanda Heslegrave; Michael D Evans; Richard J Davidson; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2021-09-15       Impact factor: 10.793

2.  Clinical evaluation and resting state fMRI analysis of virtual reality based training in Parkinson's disease through a randomized controlled trial.

Authors:  Farzin Hajebrahimi; Halil Aziz Velioglu; Zubeyir Bayraktaroglu; Nesrin Helvaci Yilmaz; Lutfu Hanoglu
Journal:  Sci Rep       Date:  2022-05-16       Impact factor: 4.996

3.  EncephalApp Stroop App predicts poor sleep quality in patients with minimal hepatic encephalopathy due to hepatitis B-induced liver cirrhosis.

Authors:  Ming Luo; Xiao-Bing Yu; Sheng-Juan Hu; Fei-Hu Bai
Journal:  Saudi J Gastroenterol       Date:  2020 May-Jun       Impact factor: 2.485

4.  Relationships between neuropsychological and antisaccade measures in multiple sclerosis patients.

Authors:  Marisa Borges Ferreira; Paulo Alexandre Pereira; Marta Parreira; Ines Sousa; José Figueiredo; João José Cerqueira; Antonio Filipe Macedo
Journal:  PeerJ       Date:  2018-10-04       Impact factor: 2.984

5.  High-Intensity Interval Cycle Ergometer Training in Parkinson's Disease: Protocol for Identifying Individual Response Patterns Using a Single-Subject Research Design.

Authors:  Erwin E H van Wegen; Mark A Hirsch; Wilma D J van de Berg; Chris Vriend; Marc B Rietberg; Mark A Newman; Tim Vanbellingen; Odile A van den Heuvel
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.